Let's list a few bullet points about ARX for the start of the new year. For anyone interested in this company, do your own research and you may find evidence for the followings:
-Solid cash position
-Approx breakeven
-Zero debt
-Proven financial discipline
-Expanding product pipeline
-Great products backed by clinical research
-High revenue growth
-Incredible high gross margin
-High quality customers (eg. large hospitals and group purchasers)
-Defensive sector
-No-nonsense, down-to-earth management
DYOR and GLTA.
Feel free to add on.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
69.5¢ |
Change
0.025(3.73%) |
Mkt cap ! $239.7M | |||
| Open | High | Low | Value | Volume |
| 69.5¢ | 69.5¢ | 66.5¢ | $227.2K | 337.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 16000 | 66.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 69.5¢ | 2363 | 1 |
View Market Depth
| Last trade - 16.10pm 18/09/2025 (20 minute delay) ? |
| ARX (ASX) Chart |